Get the Stockscreener App
6.605
6.88%
0.425
Neogenomics Inc stock is traded at $6.605, with a volume of 1.83M.
It is up +6.88% in the last 24 hours and up +2.88% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$6.18
Open:
$6.25
24h Volume:
1.83M
Relative Volume:
0.86
Market Cap:
$853.22M
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-10.65
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
+6.36%
1M Performance:
+2.88%
6M Performance:
-40.50%
1Y Performance:
-59.23%
1-Day Range:
$6.24
$6.615
1-Week Range:
$5.94
$6.615
52-Week Range:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
6.605 | 806.07M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
NeoGenomics Inc. Ranks High in Smart Money TrackerMarket Activity Report & High Accuracy Swing Trade Signals - newsyoung.net
Wyckoff Accumulation Phase Possible in NeoGenomics Inc.July 2025 Sector Moves & Low Risk Investment Opportunities - beatles.ru
NeoGenomics Reports Q2 Revenue of $181.3mln, Down from Estimates, Net Loss of $45.1mln. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics - Bluefield Daily Telegraph
Smart tools for monitoring NeoGenomics Inc.’s price action - Newser
Pomerantz LLP investigates NeoGenomics for potential securities fraud. - AInvest
Tick level data insight on NeoGenomics Inc. volatilityWeekly Trade Summary & Growth-Oriented Investment Plans - Newser
Published on: 2025-08-16 04:12:30 - Newser
Published on: 2025-08-16 03:32:01 - Newser
NeoGenomics Inc.’s volatility index tracking explainedGlobal Markets & Real-Time Stock Entry Alerts - Newser
NeoGenomics Inc. stock momentum explainedTrade Ideas & AI Optimized Trading Strategy Guides - Newser
Best data tools to analyze NeoGenomics Inc. stockWeekly Trading Summary & Safe Entry Momentum Stock Tips - Newser
What makes NeoGenomics Inc. stock price move sharplyJuly 2025 Drop Watch & High Return Trade Guides - thegnnews.com
Analyzing NeoGenomics Inc. with multi timeframe chartsSell Signal & Real-Time Volume Trigger Notifications - Newser
Published on: 2025-08-15 15:19:39 - 선데이타임즈
NeoGenomics Inc. Shows Early Signs of Technical StrengthQuarterly Trade Report & High Conviction Buy Zone Picks - classian.co.kr
Published on: 2025-08-15 08:46:44 - 선데이타임즈
Real time alert setup for NeoGenomics Inc. performanceJuly 2025 Closing Moves & Weekly High Return Forecasts - Newser
NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know - Yahoo Finance
NeoGenomics reports Q2 revenue of $181.3mln, misses estimates. - AInvest
NeoGenomics Earnings Outlook: Analysts Expect $-0.01 EPS, Guidance Key to Market Reaction - AInvest
AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know - TradingView
NEO Q2 Deep Dive: Guidance Reset Amid Pharma Weakness, Delayed Product Launches - Yahoo Finance
NeoGenomics’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
NeoGenomics Misses Q2 Revenue Estimates, Decreases FY Guidance Amid Pharma Services Challenges and Product Launch Delays. - AInvest
Can NeoGenomics Inc. sustain its profitabilityCapital Rotation Trade Suggestions - thegnnews.com
NeoGenomics Board Member Resigns Amid Valuation Concerns - AInvest
NeoGenomics Board Member Elizabeth Floegel Resigns - TipRanks
Why NeoGenomics Inc. stock attracts strong analyst attentionBuy Low Sell High Stock Watch Strategy in Focus - metal.it
Is NeoGenomics (NEO) a Short-Term Bargain or a High-Risk Speculation? - AInvest
Why NeoGenomics (NEO) Stock Is Trading Up Today - Yahoo Finance
NEOGENOMICS Executives Make Significant Stock Purchases - TradingView
NeoGenomics (NEO) Targets Opportunity at $5 billion Liquid Biopsy Market - Insider Monkey
Envestnet Asset Management Inc. Reduces Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
What are the latest earnings results for NeoGenomics Inc.Stay informed with expert market forecasts - Jammu Links News
Is NeoGenomics Inc. a good long term investmentMaximize gains with professional stock picks - Jammu Links News
What institutional investors are buying NeoGenomics Inc. stockAchieve consistent high returns with low risk - Jammu Links News
Is NeoGenomics Inc. a growth stock or a value stockInvest confidently with data-driven strategies - Jammu Links News
Should I hold or sell NeoGenomics Inc. stock in 2025Fastest-growing stock picks - Jammu Links News
NeoGenomics Inc. Stock Analysis and ForecastBuild wealth steadily with proven stock picks - Jammu Links News
How strong is NeoGenomics Inc. company’s balance sheetAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is NeoGenomics Inc. company’s growth strategyGet timely advice on market trends - Jammu Links News
How volatile is NeoGenomics Inc. stock compared to the marketGet timely alerts on market opportunities - Jammu Links News
What drives NeoGenomics Inc. stock priceUnlock daily market insights for better decisions - Jammu Links News
What is the dividend policy of NeoGenomics Inc. stockBreakneck growth rates - Jammu Links News
How many analysts rate NeoGenomics Inc. as a “Buy”Free Popular Stock Recommendations - Jammu Links News
Does NeoGenomics Inc. stock perform well during market downturnsMaximize your returns with smart trade entries - Jammu Links News
What catalysts could drive NeoGenomics Inc. stock higher in 2025High-octane financial growth - Jammu Links News
Is NeoGenomics Inc. stock overvalued or undervaluedExplosive trading opportunities - Jammu Links News
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neogenomics Inc Stock (NEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zook Anthony P. | Chief Executive Officer |
Aug 06 '25 |
Buy |
5.58 |
17,900 |
99,954 |
38,066 |
| Williams Felicia | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
7,160 |
0 |
7,160 |
| KANOVSKY STEPHEN M | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
52,344 |
| Kelly Michael Aaron | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
44,009 |
| TETRAULT LYNN A. | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
73,652 |
| Floegel Elizabeth | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Gunn Neil | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
28,100 |
| Zook Anthony P. | Chief Executive Officer |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Perez David Brian | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
33,890 |
| Kelly Michael Aaron | Director |
May 27 '25 |
Buy |
7.60 |
5,000 |
38,000 |
5,000 |
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):